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Abstract 
 
The GLP-1 receptor (GLP-1R) is a key target for type 2 diabetes (T2D) treatment. Since 
endocytic trafficking of agonist-bound receptors is one of the most important routes for 
regulation of receptor signaling, a better understanding of this process may facilitate the 
development of new T2D therapeutic strategies. Here, we have screened 29 proteins with 
known functions in G protein-coupled receptor trafficking for their role in GLP-1R 
potentiation of insulin secretion in pancreatic beta cells. We identify five (clathrin, dynamin1, 
AP2, SNX27 and SNX1) that increase and four (HIP1, HIP14, GASP-1 and Nedd4) that 
decrease insulin secretion from murine insulinoma MIN6B1 cells in response to the GLP-1 
analogue exendin-4. The roles of Huntingtin-interacting protein 1 (HIP1) and the endosomal 
sorting nexins SNX1 and SNX27 were further characterized in mouse and human beta cell 
lines and human islets. While HIP1 was required for the coupling of cell surface GLP-1R 
activation with clathrin-dependent endocytosis, the sorting nexins were found to control the 
balance between GLP-1R plasma membrane recycling and lysosomal degradation, and, in 
doing so, determine the overall beta cell incretin responses. We thus identify key modulators 
of GLP-1R trafficking and signaling that might provide novel targets to enhance insulin 
secretion in T2D. 
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The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) is a key type 2 diabetes therapeutic 
target (1). Upon agonist binding, GLP-1Rs signal through stimulatory G proteins (Gs) to raise 
intracellular cAMP levels and modulate insulin secretion from pancreatic beta cells.  
 
As with other G protein-coupled receptors (GPCRs), GLP-1R signaling is tightly regulated 
through endocytic trafficking (2). Activated GLP-1Rs are rapidly internalized and recycled to 
the plasma membrane, or distributed throughout endocytic compartments (3). Despite the 
pivotal role of trafficking in GPCR signaling, neither the molecular details nor the key factors 
responsible for GLP-1R endocytosis and post-endocytic sorting have been thoroughly 
investigated.  
 
Trafficking of the wider GPCR family has, however, been extensively characterized (4). 
Following agonist binding and G protein recruitment, GPCRs undergo phosphorylation, β-
arrestin recruitment, signal termination and sorting into clathrin-coated pits (CCPs) for 
internalization (5). β-arrestin recruitment also results in a second wave of signaling (6). Post-
endocytic GPCR sorting is critical for the spatiotemporal regulation of signaling (7), and 
involves numerous molecular players, including receptor post-translational modifications (8), 
interactions with endosomal sorting complex required for transport (ESCRT) (9), PDZ 
domain-containing proteins (10), small GTPases (11), and membrane curvature-inducing 
sorting nexins (SNXs) (12). Additionally, while endocytosis has long been associated with 
signal attenuation, recent evidence indicates that signaling also occurs from endosomes (13).  
 
In this study, we have screened 29 factors known for their roles in GPCR trafficking to 
identify those that modulate incretin-stimulated insulin secretion (ISIS). Our approach 
identifies nine factors as key regulators of incretin responses. We have further characterized 
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Huntingtin-interacting protein 1 (HIP1), an endocytic factor involved in Huntington’s disease 
(HD) (14), and the sorting nexins SNX1 and SNX27, endosomal factors associated with the 
multiprotein retromer complex (15), in GLP-1R signaling and beta cell function.  
 
Research Design and Methods 
 
Cell/islet culture  
Mouse MIN6B1 (derived from MIN6 (16)) cells were maintained as described (17). Stable 
MIN6B1-SNAP-GLP-1R and Chinese Hamster Ovary (CHO)-K1-SNAP-GLP-1R cells were 
generated by pSNAP-GLP-1R transfection, G418 selection and fluorescence-activated cell 
sorting (FACS) after labeling with SNAP-Surface 488 (New England Biolabs). CHO-K1-
GLP-1R-RLuc8 cells were generated by pGLP-1R-RLuc8 transfection, G418 selection and 
individual clone screening by luciferase assay. Human EndoC-βH1 cells were cultured as 
described (18). 
 
Human islet studies were approved by the National Research Ethics Committee London 
(REC07/H0711/114). Islets isolated from normoglycaemic donors with appropriate consent 
and ethical approval were cultured as described (19). See Supplementary Table 1 for donor 
details. 
 
Confocal microscopy 
Cells were labeled with 1 µM fluorescent SNAP-Surface probe (New England Biolabs) in 
HEPES-bicarbonate buffer (120 mM NaCl, 4.8 mM KCl, 24 mM NaHCO3, 0.5 mM 
Na2HPO4, 5 mM HEPES, 2.5 mM CaCl2, 1.2 mM MgCl2, 5% CO2, pH 7.4) plus 3 mM 
glucose and 1% BSA, stimulated with 100 nM exendin-4 plus 11 mM glucose, fixed and 
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imaged with a Zeiss LSM-780 inverted confocal microscope with a 63x/1.4 numerical 
aperture oil-immersion objective and analyzed in Image J. 
 
Cyclic AMP assays  
For static cAMP, cells were incubated in media with indicated glucose ± 100 nM exendin-
4/GLP-1 supplemented with isobutylmethylxanthine (IBMX) as indicated. Results were 
expressed versus baseline [cAMP] in IBMX. Note that exendin-4 cAMP responses were not 
affected by glucose concentration (Supplementary Fig. 1). For exendin-4 dose-responses, 
CHO-SNAP-GLP-1R cells were stimulated without phosphodiesterase inhibitors, and a curve 
fitted to a 4-parameter logistic fit. For endosomal cAMP, cells were treated with 100 nM 
exendin-4 for 15 min to allow internalization, followed by washing and 60 min in 10 µM 
GLP-1R antagonist exendin(9-39) plus 10 µM trafficking inhibitor monensin and indicated 
IBMX concentration, and results normalized to [cAMP] after 15 min exendin-4. Cyclic AMP 
was measured by cAMP Dynamic 2 homogeneous time-resolved fluorescence-based (HTRF) 
assay (Cisbio Bioassays) in a PHERAstar reader (BMG Labtech).  
 
For cAMP Förster resonance energy transfer (FRET), cells were transfected with cAMP 
sensor Citrine/Cerulean-Epac2-camps (20) and imaged in HEPES-bicarbonate buffer plus 3 
mM glucose and 100 µM IBMX before and after addition of 100 nM exendin-4. Wavelengths 
were 440 nm (excitation), 470 nm and 530 nm (emission, Cerulean and Citrine, respectively). 
FRET is Cerulean/Citrine fluorescence normalized to baseline before exendin-4. 
 
FACS Trafficking assay 
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MIN6B1-SNAP-GLP-1R cells were labeled with 1 µM cleavable BG-SS-488 SNAP-Surface 
probe (a gift from New England Biolabs) and stimulated with 100 nM exendin-4 before 
trafficking assays (21). 
 
Briefly, to measure receptor internalization, cells were cooled at 4°C to arrest endocytosis 
after incubation at 37°C for the indicated times, or put at 4°C (t=0 min), and treated with ice-
cold alkaline Tris/NaCl/EDTA (TNE) buffer (100 mM NaCl, 50 mM Tris-HCl, pH 8.6) ± 
100 mM sodium 2-sulfanylethanesulfonate (MesNa), a membrane-impermeable reducing 
agent, to strip surface-exposed label (+MesNa) or for total receptor (-MesNa). For recycling, 
cells were incubated with exendin-4 for 15 min, arrested at 4°C, MesNa-treated, incubated 
for 30 min with 10 µM exendin(9-39) to prevent further internalization, and subjected to a 
second round of surface label removal.  
 
Cells were processed by FACS using a BD LSR II flow cytometer (10,000 cells/sample) and 
analyzed with FlowJo: median fluorescence emission at 525 nm from living, single cells was 
measured, with highly auto-fluorescent cells excluded by dual fluorescence measurements at 
525 and 585 nm.   
 
The percentage of internalized receptor was calculated as follows:  
 
	 
	  − 	 
	 
1 − 	 
	 
× 100 
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Where 	 and 
	 are median fluorescence ± MesNa at time  or  (0 min). The 
% recycled receptor was calculated by subtracting residual median fluorescence following the 
recycling protocol from that measured at t=15 min, and normalizing it to % internalized 
receptor at t=15 min. 
 
Electron microscopy 
MIN6B1-SNAP-GLP-1R cells on Thermanox coverslips (Agar Scientific) were labeled with 
2 µM SNAP-Surface biotin (a gift from New England Biolabs), and 5 µg/ml NaN3-free Alexa 
Fluor 488 Streptavidin, 10 nm colloidal gold (Molecular Probes) and stimulated with 100 nM 
exendin-4. Conventional EM was performed as described (22). Ultrathin 70 nm sections were 
cut en face with a diamond knife (DiATOME) and imaged on a FEI Tecnai G2 Spirit TEM. 
Images were acquired in a CCD camera (Eagle), and gold particles quantified in Image J. 
 
Insulin secretion assays 
Cells were pre-incubated at 37°C in a Krebs-HEPES-bicarbonate (KHB) buffer [140 mM 
NaCl, 3.6 mM KCl, 1.5 mM CaCl2, 0.5 mM MgSO4, 0.5 mM NaH2PO4, 2 mM NaHCO3, 10 
mM HEPES, and 1% BSA (MIN6B1); 460 mM NaCl, 20 mM KCl, 4 mM CaCl2, 4 mM 
MgCL2, 96 mM NaHCO3 and 0.2% BSA (EndoC-βH1); 5% CO2, pH 7.4] plus 3 mM 
(MIN6B1) or 0.5 mM (EndoC-βH1) glucose, then incubated for 1 h at 37°C in KHB buffer 
plus 11 mM (MIN6B1) or 15 mM (EndoC-βH1) glucose ± 100 nM exendin-4/GLP-1 and 
supernatants and cell extracts recovered. Insulin was measured as described (23) and 
expressed as insulin stimulation index (ISI) relative to 11 or 15 mM glucose alone. Human 
islet assays were performed as described (19).  
 
TUNEL assays  
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MIN6B1 cells were incubated overnight with serum-free media plus 25 mM glucose and 0.5 
mM palmitate/BSA ± 100 nM exendin-4, processed with In Situ Cell Death Detection Kit 
(Roche), and imaged, with ≥500 cells counted per experiment. 
 
cDNA transfections and RNA interference  
Transient cDNA/siRNA transfections were performed with Lipofectamine 2000 (Life 
Technologies), for 48 and 72 h, respectively; See Supplementary Table 2 for a plasmid list. 
Mouse RNAi sequences were ON-TARGETplus Non-targeting Control Pool and 
SMARTpools from a Cherry-pick RNAi Library (Dharmacon); See Supplementary Table 3 
for details. Hamster RNAi sequences were 5’CATAATAACCAGAAGATGATT3’ (SNX1) 
and 5’GAACAAGACTGAAGAGGGATT3’ (SNX27). 
 
For HIP1 lentiviral small hairpin RNA (shRNA), a control and five human HIP1 shRNA 
constructs (Dharmacon) based on target sequences from The RNAi Consortium 
(Supplementary Fig. 6A) were transfected onto HEK293T to assess knockdown efficiency. 
Two constructs displaying the highest knockdown were selected for lentiviral particle 
production. Intact human islets were infected at multiplicity of infection (MOI) 20, and 
cultured for 72 h before analysis.  
 
Stable EndoC-βH1 SNX shRNA sublines were generated by infection with lentiviral particles 
expressing shRNA duplexes previously cloned into pLKO.3G. See Supplementary Fig. 11A 
for target sequence details. 
 
Lentiviral packaging 
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Lentiviruses were generated in HEK293T cells by co-transfection of shRNA with envelope 
and packaging vectors. Viral supernatants were harvested and purified by 20% sucrose 
gradient ultracentrifugation.  
  
Cytosolic Ca
2+
 imaging in human islets 
Ca
2+
 imaging was performed as described (24). Islets loaded with 10 µM Fluo-2 in HEPES-
bicarbonate buffer plus 11 mM glucose were imaged by sequential perifusion of 100 nM 
exendin-4 (15 min) and 20 mM KCl (4 min). Emitted signals (510–540 nm) were captured at 
30 min
-1
 frame rates, and normalized by average baseline fluorescence. 
 
Quantitative PCR 
qRT-PCR was performed using standard methodologies, with SYBR Green primers designed 
using Primer Express. 
 
Pull-down assays 
MIN6B1-SNAP-GLP-1R cells were stimulated with 100 nM exendin-4, cross-linked with 2 
mM 3,3′-dithiodipropionic acid di(N-hydroxysuccinimide ester) (DSP, Sigma), quenched 
with 20 mM Tris-HCl (pH 7.5) and lysed in 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 0.5% Triton X-100 plus cOmplete mini EDTA-free protease inhibitor (Roche) and 
phosphatase inhibitor (Sigma) cocktails. Lysates were pre-cleared with Protein G-Agarose 
beads (Roche), and incubated with SNAP-Capture Pull Down Resin beads (New England 
Biolabs). Beads were washed x5, resuspended in urea sample buffer (100 mM Tris-HCl pH 
6.8, 2.5% SDS, 4 M urea, 50 mM DTT, 0.05% bromophenol blue) and incubated for 10 min 
at 37°C before immuno-blotting.  
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Western immuno-blotting 
Lysates fractioned by SDS-PAGE under reducing conditions were immuno-blotted using 
standard methodologies. Antibodies are listed in Supplementary Table 4.  
 
Bioluminescence resonance energy transfer (BRET) saturation assay 
CHO-GLP-1R-RLuc8 cells were transfected with increasing amounts of SNX27-GFP and 
BRET assays performed as described (25). Briefly, 5 µM coelenterazine h was added, and 
bioluminescence and fluorescence recorded at 475 and 530 nm in a Flexstation 3 plate reader 
(Molecular Devices). Average BRET ratios were calculated as 530 nm / 475 nm signals, and 
net BRET values obtained by subtracting basal BRET ratio of GLP-1R-Rluc8 alone.  
 
Statistical analyses 
GraphPad Prism 7.0 was used for data analyses. ANOVA or two-tailed t-tests were 
performed throughout. Paired analyses were used in experiments with matched designs.  
 
Results 
 
RNAi Screen of GLP-1R Trafficking Regulators 
Twenty-nine factors with known effects in GPCR trafficking were selected (Supplementary 
Table 5), including regulators of post-translational modifications (HIP14, Cbl, Nedd4); β-
arrestins; clathrin-dependent (Intersectin1, HIP1, Epsin1, Eps15, AP2, clathrin, dynamin1) 
and clathrin-independent (Arf6, caveolin1) endocytosis modulators; early endosome 
biogenesis (Rab5a, AnnexinA2) and signaling (APPL1, SARA) factors; PDZ domain or 
retromer-associated factors (WASH, NHERF1, SNX27, SNX1); ESCRT associated factors 
(Hrs, Tsg101, ALIX); recycling (Rab11a, Rab4a), late endosome (GASP-1) and lysosomal 
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(v-ATPase subunit) components. Gene expression was confirmed in MIN6B1 cells with the 
exception of caveolin1, which was below detection levels (Supplementary Fig. 2A).  
 
Candidates were silenced by RNAi (Supplementary Fig. 2B) in a MIN6B1 subline stably 
expressing SNAP-tagged human GLP-1R, MIN6B1-SNAP-GLP-1R, where follow-up 
trafficking studies could be performed. Insulin secretion in response to the stable GLP-1 
analog exendin-4 was measured (Fig. 1). Factors with <10% effect were discarded in a first 
round of screening (Fig. 1A). From the remaining factors, we identified five (SNX27, 
dynamin1, AP2, clathrin, and SNX1) that increased and four (HIP1, Nedd4, HIP14, and 
GASP-1) that decreased ISIS upon gene silencing (Fig. 1B, C). We selected the factors with 
the strongest effect, i.e. Huntingtin-interacting protein 1 (HIP1) and the sorting nexin SNX27 
(together with its retromer partner, SNX1), for further analysis. 
 
HIP1 regulates GLP-1R Trafficking and Signaling 
We first determined the effect of HIP1 silencing on GLP-1R trafficking with a FACS 
trafficking assay in MIN6B1-SNAP-GLP-1R cells (see Research Design and Methods and 
Fig. 2A for details). We measured a small but significant reduction in exendin-4-induced 
SNAP-GLP-1R internalization in HIP1 versus control RNAi (Fig. 2B), without effect on 
recycling (Supplementary Fig. 3). This internalization delay was confirmed by confocal (Fig. 
2C) and electron microscopy (Fig. 2D, quantified in Fig. 2E). 
 
Whilst the MIN6B1-SNAP-GLP-1R subline allows correlation between secretion and 
trafficking, it over-expresses the GLP-1R compared to parental MIN6B1 cells 
(Supplementary Fig. 4). Experiments were therefore repeated in the more physiological 
MIN6B1 cells and primary human islets. HIP1 RNAi (Fig. 3A) caused a significant decrease 
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in insulin secretion in MIN6B1 in response to exendin-4 (Fig. 3B), as well as to the natural 
agonist GLP-1 (Supplementary Fig. 5), while glucose-stimulated insulin secretion (GSIS) 
was unaffected (Fig. 3C). Reduced GLP-1R signaling was confirmed by both static and 
dynamic (FRET) cAMP experiments (Fig. 3D, E). There was also a significant reduction in 
the protection against glucolipotoxicity-induced apoptosis by exendin-4 following HIP1 
knockdown (Fig. 3F, G). 
 
For human islets, we selected two HIP1 shRNA constructs with high knockdown efficiency 
(Supplementary Fig. 6A, B) to produce lentiviral particles. Efficient silencing was confirmed 
in human EndoC-βH1 beta cells plus dispersed (Supplementary Fig. 6C, D) as well as intact 
human islets (Fig. 4A, B), where functional studies were performed. HIP1 silencing 
significantly decreased ISIS (Fig. 4C) without affecting GSIS (Supplementary Fig. 6E). 
Exendin-4-induced cytosolic Ca
2+
 rises were also decreased (Fig. 4D, E) while Ca
2+
 response 
to KCl was unaffected (Fig. 4F).  
 
We next determined the effect of HIP1 knockdown on β-arrestin recruitment (Fig. 5A). 
Recruitment of β-arrestins to SNAP-GLP-1R was not detected under vehicle conditions 
(Supplementary Fig. 7), but was clearly present after 5 min exendin-4 in Control but highly 
reduced in HIP1 RNAi-treated MIN6B1-SNAP-GLP-1R cells. 
 
Then we performed a pull-down assay to isolate factors interacting with SNAP-GLP-1R 
following HIP1 RNAi (Fig. 5B). We isolated β-arrestin-1-mYFP and β-arrestin-2-GFP in 
complex with SNAP-GLP-1R after 5 min exendin-4 in control cells, confirming that GLP-1R 
recruits both arrestin isoforms, but this association was impaired after HIP1 knockdown. 
Additionally, we detected binding of GLP-1R to GαS-YFP in Control but not in HIP1 RNAi-
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treated cells, as well as reduced binding to tyrosine kinase Src, normally recruited to agonist-
bound GLP-1R via β-arrestin-1 (26). 
 
Finally, we performed a rescue experiment by expressing human full-length or mutant HIP1 
deleted for the clathrin-binding domain in Control or HIP1 RNAi-treated MIN6B1 cells (Fig. 
5C). As expected, full-length but not clathrin-binding deficient HIP1 restored the capacity of 
SNAP-GLP-1R to internalize with exendin-4 (Fig. 5D). However, both forms of HIP1 
rescued ISIS from HIP1-depleted cells to a similar extent (Fig. 5E), despite reduced levels of 
expression of clathrin-binding domain-deleted versus full-length HIP1 (Fig. 5C). 
 
SNX1 and SNX27 Regulate GLP-1R Recycling and Insulin Secretion 
In the second part of the study, we analyzed the roles of SNX1 and SNX27 in GLP-1R 
trafficking and signaling. We noticed a high degree of co-localisation (Fig. 6A) and protein 
interaction (Fig. 6B) between SNAP-GLP-1R and GFP-tagged SNX1 and SNX27, which was 
greater for SNX27-GFP. We confirmed the interaction between GLP-1R-RLuc8 and SNX27-
GFP by BRET (Fig. 6C). This interaction was still present for mutant SNX27 either bearing a 
point mutation in the NPxY-binding domain or lacking the PDZ domain (Supplementary Fig. 
8).  
 
We next analyzed GLP-1R trafficking by FACS following SNX silencing. Surprisingly, 
while down-regulation of both SNXs increased ISIS (Fig. 1) and cAMP (Supplementary Fig. 
9) in MIN6B1-SNAP-GLP-1R cells, SNX1 knockdown increased, while SNX27 knockdown 
decreased, SNAP-GLP-1R plasma membrane recycling (Fig. 7A, B). No effects on 
internalization were detectable. It has been reported that SNX27 silencing, while reducing 
receptor recycling, can increase signaling from endocytic compartments (27). To test this 
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hypothesis, we measured exendin-4-induced cAMP production specifically from internalized 
receptors (Fig. 7C). This revealed a significant increase following SNX27, but not SNX1, 
knockdown, suggesting that cAMP increases after SNX1 and SNX27 silencing have different 
subcellular origins. We also performed a degradation assay to measure SNAP-GLP-1R levels 
before and after exendin-4 stimulation, but did not detect any significant impact of either 
SNX RNAi (Fig. 7D). Thus, modest reductions in SNX expression (Supplementary Fig. 2B) 
primarily impact GLP-1R recycling, without affecting basal or exendin-4-induced lysosomal 
degradation.  
 
We next confirmed our findings in parental MIN6B1 cells where, following mild (~40%) 
SNX1 or SNX27 down-regulation (Fig. 7E), ISIS was again significantly increased (Fig. 7F).  
 
SNX27 depletion has been linked to reductions in basal receptor levels (28; 29). To 
investigate whether a higher degree of knockdown might also cause similar effects for GLP-
1R, we performed SNX knockdown experiments using a subline of readily transfectable 
CHO-K1 cells stably expressing SNAP-GLP-1R (CHO-SNAP-GLP-1R, Supplementary Fig. 
10), where SNX knockdown efficiency was ~70% (Fig. 8A). Exendin-4 cAMP dose response 
curves showed that, while the maximal response was increased following SNX1 down-
regulation, this was now reduced after SNX27 knockdown (Fig. 8B, left). We also 
overexpressed each SNX fused to GFP and compared cAMP responses to exendin-4 with 
those for GFP alone (Fig. 8B, right). SNX1-GFP reduced, while SNX27-GFP increased, 
maximal cAMP increases, effectively reversing the silencing results. Under these knockdown 
conditions, SNX27 RNAi-treated cells failed to sustain endosomal cAMP increases (Fig.  
8C), and displayed reduced basal levels of SNAP-GLP-1R as well as increased exendin-4-
induced receptor degradation (Fig. 8D). 
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Finally, we confirmed these results in stable SNX shRNA-expressing EndoC-βH1 human 
beta cells with silencing efficiencies of ~80% (Fig. 8E and Supplementary Fig. 11A, B). 
Exendin-4-induced cAMP and insulin responses were again increased following SNX1 
silencing, and a small but significant decrease was measured for SNX27 knockdown (Fig. 8F, 
G, also shown for GLP-1 responses in Supplementary Fig. 11C, D). Endosomal cAMP was 
again not increased in SNX27 versus control or SNX1 down-regulated EndoC-βH1 cells 
(Fig. 8H). 
 
Discussion 
 
Trafficking factors can radically alter GPCR signaling outputs (4). The GLP-1R has long 
been recognized as an important beta cell pharmacological regulator and, therefore, 
understanding the mechanisms that determine its downstream signaling is of considerable 
importance. 
 
Here, we have deployed a screen to identify trafficking factors with promising effects on 
insulin secretion downstream of GLP-1R. Importantly, the screen silencing degree was quite 
modest (20-70%, Supplementary Fig. 2B), further emphasizing the likely significance of the 
factors identified. Among factors that increased secretion after knockdown we identified 
three, dynamin1, AP2 and clathrin, involved in CCP formation (30). This, together with the 
undetectable caveolin1 expression level in MIN6B1 cells, and the reported interaction 
between GLP-1R and AP2 (31), suggests that the main route of GLP-1R internalization is 
clathrin-dependent. 
 
Page 15 of 58 Diabetes
 16
A recent report (32) has shown that near-complete abrogation of receptor internalization with 
dominant negative dynamin1 leads to reduced GLP-1R signaling. The apparent discrepancy 
between this and our results may be related to the modest knockdown level achieved here for 
dynamin1. We hypothesize that a modest reduction in receptor internalization would preserve 
endosomal while allowing increased cell surface receptor signaling, resulting in overall 
signaling increases. In contrast, near-complete inhibition of internalization might have 
detrimental effects due to complete abrogation of endosomal signaling and unmitigated β-
arrestin-dependent cell surface receptor desensitization.  
 
Silencing of individual β-arrestins had no significant effect on ISIS in our screen. This is in 
agreement with a recent report (33) showing normal GLP-1-induced insulin secretion in β-
arrestin-2 knockout mice, and might reflect some degree of redundancy between β-arrestin 
isoforms (although we note that β-arrestin-2 is >10-fold more expressed in MIN6B1 than β-
arrestin-1: see Supplementary Fig. 2A). Alternatively, there may be compensation between 
increased plasma membrane but reduced β-arrestin-dependent or endosomal signaling. 
Among factors that reduced ISIS following knockdown, we found some involved in post-
translational modifications, such as the palmitoyl transferase HIP14 (34), or the ubiquitin 
ligase Nedd4 (35), as well as the late endosomal signaling factor GASP-1 (36). 
 
Silencing of HIP1, an endocytic factor involved in clathrin-dependent receptor internalization 
(37), gave the strongest effect by decreasing ISIS, in contrast to other CCP components. This 
correlates with previous reports linking HIP1 with enhanced receptor activity and increased 
signaling (38). Loss of HIP1 also led to reduced exendin-4-induced SNAP-GLP-1R 
internalization, cAMP and cytosolic Ca
2+
 responses. Biochemical and structural studies have 
led to a “two-step” model of class B1 GPCR activation where, following agonist binding to 
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free receptor, this “collides” with free G proteins (39), initiating the G protein signaling 
cascade. Our pull-down assays suggest that, in the absence of HIP1, GLP-1R displays 
reduced G protein coupling, providing a mechanistic explanation for the observed reductions 
in receptor signaling and insulin secretion. As a result, there is impaired recruitment of β-
arrestins and downstream factors such as Src.  
 
Our rescue experiment not only confirms the importance of HIP1, but also unveils a role in 
coupling of GLP-1R activation with clathrin-dependent endocytosis. HIP1 role in 
internalization appears not to be required for cell surface receptor signaling, as even with 
impaired internalization, HIP1 mutants unable to bind to clathrin rescued ISIS to the same 
extent as full-length HIP1 in HIP1-depleted cells. Notably, this was achieved despite reduced 
expression of mutant versus full-length HIP1, indicating that, in agreement with results 
obtained here for other CCP factors, reduced GLP-1R internalization when HIP1 is otherwise 
functional for receptor activation increases ISIS.    
 
HIP1 interacts with the protein huntingtin in neurons, which, in its mutated form in the 
neurodegenerative syndrome HD, cannot associate with HIP1. Of interest is that patients with 
HD also present with impaired glucose handling, at least partially due to beta cell dysfunction 
(14). This dysfunction, and the general neurodegeneration, is alleviated by treatment with 
GLP-1R agonists including exendin-4 (40). While the effects of mutated huntingtin are 
complex and pleiotropic, it is possible that part of the glucose dysfunction is linked to 
deregulation of GLP-1R signaling and hence directly ameliorated by pharmacological GLP-
1R activation. 
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Additionally, knockdown of the two sorting nexins in our screen, SNX27 and SNX1, led to 
increased exendin-4-induced cAMP and insulin secretion in MIN6B1-SNAP-GLP-1R cells. 
SNX1 interacts in vitro with the C-terminal domain of GLP-1R (41), and we demonstrate 
here this interaction in beta cells. SNX1 plays an important role in GPCR sorting towards 
degradation (42), but it has also been implicated in GPCR recycling modulation without 
affecting lysosomal turnover (43). Our findings are consistent with a role for SNX1 on 
restricting the rate of GLP-1R recycling without affecting overall degradation, leading to 
consistent increases on GLP-1R signaling and ISIS following its down-regulation.  
 
SNX27, on the other hand, is involved in membrane tubulation and receptor sorting from 
early to recycling endosomes (44). Here we have found, for the first time, that GLP-1R 
strongly associates and interacts with SNX27 in beta cells. This is somewhat surprising as 
most associations of GPCRs with SNX27 are mediated by interactions between the SNX27 
PDZ domain and PDZ-binding motifs at receptor C-terminal domain (45). The GLP-1R does 
not contain a canonical PDZ-binding motif, and, consequently, binds to SNX27 after deletion 
of its PDZ domain. While the domain involved in binding between GLP-1R and SNX27 is 
not elucidated, it is interesting to note that a second receptor barcode, formed of sequence 
determinants or conserved phosphorylation sites, has recently been revealed to dramatically 
enhance interactions between GPCRs and SNX27 (45). 
 
SNX27 serves as a cargo adaptor for retromer-mediated transport to the cell surface (46), 
and, accordingly, we found a significant reduction in GLP-1R cell surface recycling 
following SNX27 knockdown. Intriguingly, despite reduced cell surface levels, GLP-1R 
signaling remained elevated in MIN6B1 and MIN6B1-SNAP-GLP-1R cells. Concomitantly, 
we found elevated signaling from internalized receptors, indicating that SNX27 integrates 
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plasma membrane recycling and retromer-mediated GLP-1R signal termination, as seen for 
other GPCRs such as the parathyroid hormone receptor (47). Direct association of retromer 
with GLP-1Rs might occur via structural similarity of the VPS26 retromer subunit to β-
arrestins (48), perhaps explaining the association between GLP-1R and SNX27 in the 
absence of a PDZ-binding motif. 
 
Depletion of SNX27 is associated with defective constitutive receptor recycling and 
increased lysosomal turnover (49; 50). The results from MIN6B1-SNAP-GLP-1R cells 
imply, however, that under mild SNX27 knockdown, sufficient basal levels of GLP-1R are 
maintained to enable overall incretin-induced cAMP increases, with compensatory 
mechanisms such as increased GLP-1R translation likely. Indeed, under these conditions, we 
did not detect a significant decrease in basal levels of SNAP-GLP-1R. However, with more 
efficient SNX27 knockdown, such as in CHO-SNAP-GLP-1R cells, basal SNAP-GLP-1R 
levels were significantly reduced, in agreement with continuous missorting of receptors to 
degradative compartments. As a consequence, in these and in EndoC-βH1 SNX27 shRNA 
cells, GLP-1R signaling and ISIS were blunted, and elevated endosomal cAMP no longer 
detected. 
 
In conclusion, we have identified nine endocytic factors as regulators of ISIS of potential 
importance for GLP-1R responses in health and diabetes. We show that one of them, HIP1, is 
required for establishment of plasma membrane incretin responses, while SNX1 and SNX27 
control GLP-1R recycling and turnover, determining overall GLP-1R outputs. Agents that 
affect interactions between these trafficking regulators and the GLP-1R may in the future 
provide interesting new targets to improve the efficacy of incretin-based T2D therapies. 
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Figure Legends 
 
Figure 1. RNAi screen of GPCR endocytic trafficking regulators in MIN6B1-SNAP-
GLP-1R cells. A: First round screen of incretin-stimulated insulin secretion (ISIS) following 
RNAi silencing of 29 candidate trafficking regulators. Results are expressed as mean ± SEM 
of insulin stimulation index (ISI) for each candidate of exendin-4 in 11 mM glucose (G11) 
relative to G11 alone, and normalized to Control RNAi for each candidate; n=3. Grey bar 
represents 10% cut-off effect on ISI vs. Control RNAi. B: Further analysis of ISIS following 
knockdown of 18 candidates selected from the initial screen; Results expressed as above; 
n=3-8. Factors with significant up-regulated secretion after RNAi are depicted in blue, while 
those with significant RNAi-induced down-regulation of secretion are in red. C: Individual 
results for each of the factors from (B) presenting a significant ISIS effect after knockdown, 
relative to paired Control RNAi experiments. Data are expressed as mean ± SEM of exendin-
4 plus G11 ISI relative to G11 alone; n=3-8, *p<0.05 and **p<0.01, two-tailed paired t-tests. 
Individual data points are shown. 
 
Figure 2. Role of HIP1 in GLP-1R trafficking in MIN6B1-SNAP-GLP-1R cells. A: 
Schematic showing the protocol for FACS analysis of SNAP-GLP-1R trafficking. B: 
Percentage of SNAP-GLP-1R internalization following treatment with 100 nM exendin-4 in 
Control vs. HIP1 RNAi-treated MIN6B1-SNAP-GLP-1R cells; data are expressed as mean ± 
SEM, n=3, *p<0.05 and ***p<0.001, two-way randomized block ANOVA with Sidak’s test. 
C: Confocal microscopy results showing SNAP-Surface-488-labelled SNAP-GLP-1R (green) 
in Control vs. HIP1 RNAi-treated MIN6B1-SNAP-GLP-1R cells after 15 min stimulation 
with 100 nM exendin-4. Nuclei (DAPI), blue; size bars, 10 µm. D: Electron microscopy 
localization of SNAP-GLP-1R (gold particles, arrows) in Control vs. HIP1 siRNA-
transfected MIN6B1-SNAP-GLP-1R cells treated as above; size bars, 1 µm. After 15 min 
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stimulation with exendin-4, the receptor is present in the MVB/LE/lysosomal compartment in 
Control RNAi but is still primarily localized to PM/EEs following HIP1 RNAi; PM: plasma 
membrane; EE: early endosome; MVB: multivesicular body; LE: late endosome. E: Gold-
particle quantification of percentage of SNAP-GLP-1R in each subcellular organelle; data are 
expressed as mean ± SEM, n=2, *p<0.05, two-tailed paired t-test. PM: plasma membrane; 
EE: early endosome; MVB LM: multivesicular body limiting membrane; MVB ILV: 
multivesicular body intraluminal vesicles; Tub/RE: tubular/recycling endosome; LE: late 
endosome. 
 
Figure 3. Effect of HIP1 RNAi on incretin responses from MIN6B1 cells. A: Knockdown 
efficiency determined by qRT-PCR in MIN6B1 cells at 48 h, relative to Control RNAi; Data 
are expressed as mean ± SEM, n=8, ****p<0.0001, two-tailed t-test. Individual data points 
are shown. B: Exendin-4-stimulated insulin secretion of Control vs. HIP1 RNAi-treated 
MIN6B1 cells. Data are expressed as mean ± SEM of exendin-4 plus G11 ISI relative to G11 
alone; n=4, *p<0.05, two-tailed paired t-test. Individual data points are shown. C: Glucose-
stimulated insulin secretion of Control vs. HIP1 RNAi-treated MIN6B1 cells from (B). Data 
are expressed as mean ± SEM of insulin secreted at G11 as percentage of total insulin; n=4, 
non-significant (n.s.), two-tailed paired t-test. Individual data points are shown. D: Incretin-
induced cAMP following 1 h treatment with 100 nM exendin-4 + 100 µM IBMX in Control 
vs. HIP1 RNAi-treated MIN6B1 cells. Data are expressed as mean ± SEM of exendin-4 + 
100 µM IBMX relative to 100 µM IBMX alone; n=5, *p<0.05, two-tailed paired t-test. 
Individual data points are shown. E: cAMP FRET time-course response (left) and area under 
the curve (AUC, right) for 10 min stimulation with 100 nM exendin-4 plus 100 µM IBMX in 
Control vs. HIP1 RNAi-treated MIN6B1 cells. Data is normalized to baseline (recorded for 5 
min prior to exendin-4 addition) and expressed as mean ± SEM; n=8 cells from 4 
Page 28 of 58Diabetes
 29
independent experiments, **p<0.01, two-tailed paired t-test. Individual data points are 
shown. F: Percentage of TUNEL-positive MIN6B1 cells following overnight incubation with 
0.5 mM palmitate/BSA in the presence or absence of 100 nM exendin-4 (Ex-4). Data are 
mean ± SEM; n=5, *p<0.05, two-tailed paired t-test. Individual data points are shown. G: 
Percentage of TUNEL-positive MIN6B1 cells transfected with Control vs. HIP1 siRNA 
following overnight incubation with 0.5 mM palmitate/BSA + 100 nM exendin-4. Data are 
mean ± SEM; n=7, *p<0.05, two-tailed paired t-test. Individual data points are shown. 
TUNEL staining in untreated (no palmitate or exendin-4 added) cells was typically < 5%. 
 
Figure 4. Effect of HIP1 knockdown on incretin responses from human donor islets. A: 
Knockdown efficiency determined by qRT-PCR at 72 h from intact human islets infected 
with human HIP1 shRNA lentiviruses, relative to Control shRNA infection; n=2; HIP1 
shRNA TRCN0000033446: TRCN446; HIP1 shRNA TRCN0000033447: TRCN447; 
*p<0.05 vs. Control shRNA, two-tailed paired t-test. Individual data points are shown. B: 
Western blot analysis of HIP1 levels (top) from lysates of intact human islets infected with 
lentiviruses for Control shRNA or HIP1 shRNA TRCN446 or TRCN447 for 72 h, with 
Tubulin as loading control (bottom). C: ISIS from human donor islets infected with Control 
vs. HIP1 shRNA lentiviruses TRCN446 or TRCN447. Data are expressed as mean ± SEM of 
exendin-4 + G11 ISI relative to G11 alone; n=4, *p<0.05 and **p<0.01 vs. Control shRNA, 
one-way randomized block ANOVA with Dunnett’s test. Individual data points are shown. 
D: Ca
2+
 time-course responses from Fluo-2-loaded human islets infected with Control vs. 
HIP1 shRNA lentivirus TRCN446 following sequential stimulations with exendin-4 (100 
nM, 15 min) and KCl (20 mM, 4 min). E, F: AUC corresponding to exendin-4 (E) or KCl (F) 
responses from (D), calculated from data normalised to baseline. Data are expressed as mean 
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± SEM; n= 3 (9-13 islets imaged per experiment), *p<0.05 and non-significant (n.s.), two-
tailed paired t-test. Individual data points are shown. 
 
Figure 5. Regulation of GLP-1R activation by HIP1. A: Confocal microscopy showing co-
localization of SNAP-GLP-1R and either β-arrestin-1-mYFP (Barr1-mYFP) or β-arrestin-2-
GFP (Barr2-GFP) in Control (top) or HIP1 RNAi-treated MIN6B1-SNAP-GLP-1R cells 
(bottom) following 5 min of 100 nM exendin-4 exposure. β-arrestin-1-mYFP or β-arrestin-2-
GFP (green), SNAP-GLP-1R (labeled with SNAP-Surface-549, red), nuclei (DAPI), blue; 
size bars, 10 µm.  B: SNAP-Capture pull-down of SNAP-GLP-1R with β-arrestin-1-mYFP, 
β-arrestin-2-GFP or GαS-YFP, from lysates of Control vs. HIP1 RNAi-treated MIN6B1-
SNAP-GLP-1R cells after 5 min exposure to 100 nM exendin-4 (top). Pulled-down proteins 
analyzed by Western blot for GFP/mYFP, β-arrestin-1/2 and Src. Original lysates analyzed 
by Western blot for SNAP to assess levels of SNAP-GLP-1R and Tubulin as loading control 
(bottom). C: Western blot analysis of human HIP1 levels (top) in lysates from Control or 
mouse HIP1-RNAi-treated MIN6B1 cells re-transfected with empty pcDNA3.1 or plasmids 
expressing human full-length HIP1 (pcDNA3/FLHIP1) or mutant HIP1 with deleted clathrin-
binding domain (pcDNA3/HIP1/∆LD); with Tubulin as loading control (bottom). Note that 
cells were re-transfected with DNA plasmids 24 h after initial RNAi transfection and further 
incubated for 48 h before experiments; and that the HIP1 antibody used in this study 
primarily detects human rather than mouse HIP1. D: Confocal microscopy results showing 
SNAP-Surface-488-labeled SNAP-GLP-1R (green) in HIP1 RNAi-treated MIN6B1-SNAP-
GLP-1R cells re-transfected with plasmids as in (C) following 15 min stimulation with 100 
nM exendin-4. Nuclei (DAPI), blue; size bars, 10 µm. E: ISIS of Control vs. HIP1 RNAi-
treated MIN6B1 cells re-transfected with each of the 3 plasmids shown in (C) and (D). Data 
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are expressed as mean ± SEM of exendin-4 + G11 ISI relative to G11 alone; n=3, *p<0.05 vs. 
Control shRNA + pcDNA3.1, one-way randomized block ANOVA with Dunnett’s test. 
 
Figure 6. Association of SNAP-GLP-1R with SNX1-GFP and SNX27-GFP. A: Confocal 
microscopy showing co-localization of SNAP-GLP-1R and either SNX1-GFP or SNX27-
GFP in MIN6B1-SNAP-GLP-1R cells following 15 min treatment with 100 nM exendin-4. 
SNX1-GFP or SNX27-GFP (green), SNAP-GLP-1R (labeled with SNAP-Surface-549, red), 
nuclei (DAPI), blue; size bars, 10 µm. B: SNAP-Capture pull-down of SNAP-GLP-1R with 
either SNX1-GFP or SNX27-GFP from MIN6B1-SNAP-GLP-1R cell lysates after 15 min 
exposure to 100 nM exendin-4 or GLP-1. Pulled-down proteins analyzed by Western blot for 
GFP, original lysates immuno-blotted to assess levels of expression of GFP-tagged SNX 
constructs. C: Saturation curves from BRET ratios with the indicated amounts of SNX27-
GFP plasmid DNA in CHO-GLP-1R-RLuc8 cells following 15 min treatment with 100 nM 
exendin-4. Data is mean ± SEM; n=3. 
 
Figure 7. Effect of SNX1 and SNX27 RNAi on GLP-1R trafficking and incretin 
responses from MIN6B1 cells. A, B: Percentage of SNAP-GLP-1R internalization (top) and 
recycling (bottom) following treatment with 100 nM exendin-4 in Control vs. SNX1 (A) or 
SNX27 (B) RNAi-treated MIN6B1-SNAP-GLP-1R cells; data are expressed as mean ± SEM, 
n=3, *p<0.05 and **p<0.01; two-tailed paired t-test. Individual data points are shown for 
recycling. C: Incretin-induced cAMP specifically from GLP-1Rs internalized into 
endosomes, measured after 15 min treatment with 100 nM exendin-4 followed by washout 
and 60 min incubation in 10 µM exendin(9-39) plus 10 µM trafficking inhibitor monensin 
and 500 µM IBMX in Control vs. SNX1 or SNX27 RNAi-treated MIN6B1-SNAP-GLP-1R 
cells. Data are expressed as mean ± SEM of results normalized to 15 min exendin-4; n=4, 
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*p<0.05, one-way randomized block ANOVA with Dunnett’s test. Individual data points are 
shown. D: Western blot analysis of SNAP-GLP-1R levels in Control vs. SNX1 or SNX27 
RNAi-treated MIN6B1-SNAP-GLP-1R cells before and after exposure to 100 nM exendin-4 
for the indicated times. Cells were pre-treated for 1 h with 100 µg/ml of cycloheximide 
before exendin-4 treatment. Lysates were analyzed by Western blot with anti-SNAP to assess 
levels of SNAP-GLP-1R (top) and Tubulin as loading control (bottom). A degradation band 
corresponding to deletion of the receptor C-terminal domain is typically detected under all 
conditions analyzed. E: SNX1 and SNX27 knockdown efficiencies determined by qRT-PCR 
(at 48 h, top) and Western blotting (at 72 h, bottom) in MIN6B1 cells, relative to Control 
RNAi; Data are expressed as mean ± SEM, n=4, **p<0.01, two-tailed t-test. Individual data 
points are shown. F: ISIS of Control vs. SNX1 (top) or SNX27 (bottom) RNAi-treated 
MIN6B1 cells. Data are expressed as mean ± SEM of exendin-4 + G11 ISI relative to G11 
alone; n=6 for SNX1 RNAi and n=5 for SNX27 RNAi, *p<0.05, two-tailed paired t-test. 
Individual data points are shown. 
 
Figure 8. Effect of SNX1 and SNX27 RNAi on incretin responses from CHO-SNAP-
GLP-1R and EndoC-βH1 cells. A: SNX1 (left) and SNX27 (right) knockdown efficiencies 
in CHO-SNAP-GLP-1R cells determined by qRT-PCR at 48 h, relative to Control RNAi; 
Data are expressed as mean ± SEM, n=4, **p<0.01 and ***p<0.001, two-tailed t-test. 
Individual data points are shown. B: cAMP responses from CHO-SNAP-GLP-1R cells 
treated with Control vs. SNX1 or SNX27 RNAi (left) or expressing GFP vs. SNX1-GFP or 
SNX27-GFP (right), following 15 min exendin-4 incubation; Results normalized to forskolin 
responses, 4-parameter logistic fit of mean data ± SEM; n=4, *p<0.05, **p<0.01 and 
****p<0.0001 vs. Control RNAi or empty GFP, two-way randomized block ANOVA with 
Dunnett’s test. C: Incretin-induced cAMP specifically from GLP-1Rs internalized into 
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endosomes, measured after 15 min treatment with 100 nM exendin-4 followed by washout 
and 60 min incubation in 10 µM exendin(9-39) plus 10 µM trafficking inhibitor monensin in 
Control vs. SNX1 or SNX27 RNAi-treated CHO-SNAP-GLP-1R cells. Data are expressed as 
mean ± SEM of results normalized to 15 min exendin-4; n=5, non-significant, one-way 
randomized block ANOVA with Dunnett’s test. Individual data points are shown. D: Western 
blot analysis of SNAP-GLP-1R levels in Control vs. SNX1 or SNX27 RNAi-treated CHO-
SNAP-GLP-1R cells before and after exposure to 100 nM exendin-4 for 6 h. Lysates were 
analyzed by Western blot with anti-SNAP to assess levels of SNAP-GLP-1R (top) and with 
Tubulin as loading control (bottom). A degradation band corresponding to deletion of the 
receptor C-terminal domain is typically detected under all conditions analyzed. E: SNX1 
(left) and SNX27 (right) knockdown efficiencies in Control vs. SNX1 or SNX27 EndoC-βH1 
shRNA sublines determined by Western blotting, with Tubulin as loading control (bottom). 
F: Exendin-4-induced cAMP following 15 min treatment with 100 nM exendin-4 plus 500 
µM IBMX in Control vs. SNX1 or SNX27 shRNA EndoC-βH1 sublines. Data are expressed 
as mean ± SEM of exendin-4 + 500 µM IBMX relative to 500 µM IBMX alone; n=6, 
*p<0.05, one-way randomized block ANOVA with Dunnett’s test. Individual data points are 
shown. G: Exendin-4-stimulated insulin secretion of Control vs. SNX1 or SNX27 shRNA 
EndoC-βH1 sublines. Data are expressed as mean ± SEM of exendin-4 + 15 mM glucose 
(G15) ISI relative to G15 alone; n=6, *p<0.05, one-way randomized block ANOVA with 
Dunnett’s test. Individual data points are shown. H: Incretin-induced cAMP specifically from 
GLP-1Rs internalized into endosomes, measured as in (C) but in Control vs. SNX1 or SNX27 
shRNA EndoC-βH1 sublines. Data are expressed as mean ± SEM of results normalized to 15 
min exendin-4; n=5, non-significant, one-way randomized block ANOVA with Dunnett’s 
test. Individual data points are shown. 
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Online Supplemental Materials  
 
 
Supplementary Table 1: Origin and characteristics of human islets donors. 
 
 
Supplementary Table 2: List and origin of plasmids included in the study. 
Arrival date Isolation Centre Donor Age Sex BMI (kg/m²)
17.01.17 Pisa 64 Male 24.5
10.02.17 Milan 57 Female 26.0
15.02.17 Edmonton (Shapiro) 51 Male 29.4
23.02.17 Edmonton (Macdonald) 38 Male 42.6
14.03.17 Pisa 42 Male 32.6
23.03.17 Milan 49 Female 20.6
24.03.17 Edmonton (Shapiro) 33 Female 46.5
23.05.17 Oxford 46 Female 35.0
18.09.17 Pisa 84 Male 23.2
25.10.17 Oxford 57 Male 24.0
03.11.17 Geneva 51 Female 44.1
Plasmid Name Source
pSNAP-GLP-1R Cisbio Bioassays
Cloned from GLP-1R-GFP (Alessandro Bisello, University of Pittsburgh) 
into pcDNA3.1-RLuc8 (Aylin Hanyaloglu, Imperial College London)
β-arrestin-1-mYFP Robert Lefkowitz, Addgene plasmid #36916
β-arrestin 2-GFP Aylin Hanyaloglu, Imperial College London
GαS-YFP Catherine Berlot, Addgene plasmid #55781
SNX1-GFP Hiromichi Shirataki, Dokkyo Medical University, Japan
SNX27-GFP Isabel Mérida, National Center for Biotechnology, Spain
SNX27ΔPDZ-GFP Isabel Mérida, National Center for Biotechnology, Spain
SNX27 W475A-GFP Isabel Mérida, National Center for Biotechnology, Spain
pMD2.G Didier Trono, Addgene plasmid #12260
psPAX2 Didier Trono, Addgene plasmid #12259
pcDNA3/FLHIP1 Theodora Ross, Addgene plasmid #29587
pcDNA3/HIP1/ΔLD Theodora Ross, Addgene plasmid #31253
pLKO.3G Christophe Benoist & Diane Mathis, Addgene plasmid # 14748
pGLP-1R-RLuc8
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Supplementary Table 3: Mouse siRNA sequences for the trafficking genes 
included in the screen. A mixture of four pre-designed siRNA sequences with 
antisense strand seed regions modified to destabilize off-target activity were used. 
 
 
Supplementary Table 4: List of antibodies used in the study. 
 
Candidate name siRNA sequence 1 siRNA sequence 2 siRNA sequence 3 siRNA sequence 4
SNX27 GAACCAGGUAAUAGCGUUU CAAAUUAGCUGCACGUAUA ACGGUUACUGUCAGAGUUA GCAAAAUAGGGCACUGAUA
Dynamin1 GCGUGUACCCUGAGCGUGU UGGUAUUGCUCCUGCGACA GGGAGGAGAUGGAGCGAAU GCUGAGACCGAUCGAGUCA
AP2 CCACAAUGAGCCUCCGAAU GGUAGUGACUGCAGCGACU CACUAGGUGUGGUCAGUUA GCGAUGAUGUGCAGGGCUA
Clathrin light chain GGAAAGCAAUCCAUACAGA UCAGAAGAAUUGCUGCUUA GACAAAUUCAUCUGCAUUA ACAAAGCAAUCCAGUUCUA
SNX1 UUACCGAUGUUCAGAAGUA GCGCUGGUCUCCUUAAGAU UGAAUCAUCCCACCAUGUU AAUCUCGGGUGACUCAGUA
Rab5a AGAAGCCAGUGUUGUAGUA GCACAAGCAGCCAUAGUUG UGUGAUAGCUUUGUCAGGA UUAGAAGACUUACGCUUAA
Caveolin1 GCUAUUGGCAAGAUAUUCA GCACAUCUGGGCGGUUGUA GCAAAUACGUGGACUCCGA GUCCAUACCUUCUGCGAUC
Epsin1 ACGAUAAGGAAGAGCGGAU GGUGUGAAUGUGCGGGAGA UCUCAGACUUCGACCGACU CGGCGUCAGAUGAAGAAUA
ALIX GAACCUAGCAACUGCGUAU ACAUAGUGUUUGCACGGAA GCUACAACCCCUACGCAUA AGCCAGAAGUUCACGGAUU
Rab4a GGUCAUCGGAAAUGCGGGA GAUAAUAAAUGUCGGUGGU GUGAACAGCCAGUGCGUUU UGUCCGAGACUUACGAUUU
NHERF1/EBP50 AGAUCUGCCUCCAGCGAUA GGGACCAGAAUGAGGCCGA CCAGGAGAAGUCCGAACAA GUCCAAAUGGCUACGGCUU
WASH ACAGCAACACGGCGGAAUA GAGGAGAAAUUGUUCGAUG GCACAUUCAGGAACGUUUA GAAUACGGCUCCAUCUUUA
Hrs CAAGAUACCUCAACCGGAA AAGCAUCACUGCCGAGCAU CGUACAAUAUGCAGAAUCU AGACAGACUCUCAGCCCAU
SARA GUAUAAAGCAAACGGAAAA ACAGAGAGGAAACGAGAAU AUGAAUGGGUCCACGGAAA CUAAAUGAGAUGAGUGAUA
β-arrestin-1 UGGAUAAGGAGAUCUAUUA GGAGAACCCAUCAGCGUUA UCAUAGAGCUUGACACCAA ACGGGAAGCUCAAGCAUGA
Tsg101 CUUAAUGCCUUGAAACGAA GUACAAUCCCAGUGCGUUA CUGUCAAUGUCAUCGCUAU AGAGAUGGUCACCCGCUUA
Eps15 CAGCAGUAAUACAUCGGUA CAGCCAACUUCAACGAACA AGAAAGUUACUCCGAGAUU CUGGAAGGGUGUUGGCGUU
APPL1 GGUCAAGGAGGCAGGCGUA GGAACAAGAUAACGAUAUA GGACAGAGUUAGCGUGUAC GAUCGUAGGGCAUCAGAAA
Intersectin1 CCAGAACGAUGACGAACUA GCAAAGAGCAGGAGCGGUU GAGAGAGCCAAGCCGGAAA GGAAGGGCUACAAGCGCAA
Rab11a GUACAGGGCUAUAACGUCU UAAGAGUGAUUUACGUCAU GCGACGACGAGUACGACUA UAACAGAGAUAUACCGCAU
β-arrestin-2 GGGCCUGUCUUUCCGCAAA CUACUUGAAGGACCGGAAA AUACCAACCUCAUCGAAUU GUGCCAAAUCAAUAGAAGA
Cbl GAGAAUCAACUCAGAACGA CGUUUGGGUCAGUGGGCUA CCGGAUUACUAAAGCUGAU CGUCAGUCAUAUAUAGAUU
V-ATPase subunit A1 UGAUUAACCGGGAGCGGAU AGACAUCUUAUCCGGAAUA CGAGAUGGGAAGAGGCGCA GCUAAGAACAUCCGCGUCU
AnnexinA2 GCUCAGUUAUUGACUACGA GGACAUUGCCUUCGCCUAU CCAGUAUGAUGCUUCGGAA GCAAAGGGCAGACGAGCAG
Arf6 CAAACGGGGUGGGGUAAUA CUGACAUUUGACACGAAUA CGGCAUUACUACACCGGGA GGGUCUGAUCUUCGUGGUA
GASP-1 CCGAGAAAUUCGCGAGCAU ACGCAAACCUGGCAAUCAA GAGACUAUCAGUAAACAUA GCGAGAAGCUUGCAGUGAU
HIP14 GGGUUACGAUGUACGGCAA GAUGAGUACGAGACCGAAA GUUAAUGUAUGGUGGCGUU AGAACCUCUUGGUCGGAAA
Nedd4 GGAAGGACCUACUACGUAA GAAUAUUCUGCUACGGAUA GGAUGAUGGAUUCGGAAAA CUACGAAUCCUUUGACGAA
HIP1 ACAGAGGUAUAGCAAGUUA GGAGAAUGCUGACGUCACA CAUCCAAGGUGAAAGCGAA CGAAAUGGCUGACACAGAU
Name Species Source Dilution
Anti-GFP Rabbit ab290, Abcam 1/1000
Anti-β-arrestin-1/2 Rabbit D24H9, Cell Signaling 1/1000
Anti-SNAP tag Rabbit New England Biolabs 1/500
Anti-Src Rabbit 2108, Cell Signaling 1/1000
Anti-HIP1 Mouse 4B10, Novus Biologicals 1/500
Anti-SNX1 Rabbit ab134126, Abcam 1/500
Anti-SNX27 Rabbit NBP1-45283, Novus Biologicals 1/1000
Anti-α-Tubulin Mouse T5168, Sigma Aldrich 1/1000
IgG-HRP Goat Santa Cruz Biotechnology 1/5000
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Supplementary Table 5: List of screened candidate proteins with main known 
GPCR trafficking roles.  
 
 
 
 
 
 
 
 
 
Candidate name Trafficking function
SNX27 Retromer associated, PDZ domain, receptor sorting and recycling
Dynamin1 GTPase, actin binding, clathrin-coated pit scission
AP2 Clathrin adaptor complex subunit, cargo selection
Clathrin light chain Vesicle scaffold, clathrin-coated pit structure
SNX1 PX domain, receptor sorting to lysosomes or recycling endosomes, retromer-associated Golgi retrograde transport
Rab5a Small GTPase, early endosome biogenesis and function, recruitment of Rab7 and endosomal maturation
Caveolin1 Scaffolding protein, caveolae component, plasma membrane domian sorting
Epsin1 Membrane curvature factor, PIP2-binding, clathrin-coated pit formation
ALIX ESCRT-associated protein, cargo sorting and intraluminal vesicle (ILV) formation in endosomes
Rab4a Small GTPase, receptor sorting and recycling to the plasma membrane, fast recycling pathway
NHERF1/EBP50 Adaptor molecule, PDZ domain, protein complex assembly, binds actin machinery, receptor recycling
WASH Arp2/3 activator of actin polymerisation, receptor sorting, retromer associated, regulates endosomal fission
Hrs ESCRT-0 complex member, ubiquitinated cargo recognition in early endosomes
SARA FYVE domain protein, downstream signal transduction from early endosomes
β-arrestin-1 Agonist-mediated receptor desensitization, receptor internalisation, endosomal signalling
Tsg101 ESCRT-1 complex member, biogenesis of the multivesicular body (MVB), ILV formation
Eps15 Scaffolding adaptor protein, clathrin-coated pit component
APPL1 Early endosome associated, signal transduction factor
Intersectin1  Receptor internalisation, dynamin-binding, coordinates endocytic traffic with actin assembly
Rab11a Small GTPase, receptor slow recycling throught perinuclear recycling compartment
β-arrestin-2 Agonist-mediated receptor desensitization, receptor internalisation, endosomal signalling
Cbl E3 ubiquitin ligase, receptor ubiquitination, regulates receptor lysosomal degradation
V-ATPase subunit A1 Vacuolar ATPase, organelle acidification, lysosomal function
AnnexinA2 Endosome biogenesis, regulation of membrane and actin dynamics
Arf6 Small GTPase, cytoskeleton remodeling, plasma membrane recycling, clathrin-independent endocytosis
GASP-1 Modulation of lysosomal transport of receptors, post-endocytic sorting 
HIP14 Palmitoyl transferase, receptor palmitoylation, endocytosis factor, interaction with huntingtin (htt) 
Nedd4 E3 ubiquitin ligase, receptor signalling regulation, ubiquitination of endocytic factors
HIP1 Binds clathrin-pit components, interacts with htt, receptor signaling coupling with clathrin-mediated endocytosis
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Supplementary Figure 1. Effect of glucose on exendin-4-induced cAMP 
responses. A: Incretin-induced cAMP in MIN6B1 cells following 15 min treatment 
with 100 nM exendin-4 plus 100 µM IBMX in the indicated glucose concentrations. 
Data are expressed as mean ± SEM of exendin-4 plus 100 µM IBMX relative to 100 
µM IBMX alone; n=8, non-significant, two-tailed paired t-test. B: As for (A) but in 
EndoC-βH1 cells treated with 100 nM exendin-4 + 500 µM IBMX in the indicated 
glucose concentrations. Data are expressed as mean ± SEM of exendin-4 plus 500 µM 
IBMX vs. 500 µM IBMX alone; n=4, non-significant, two-tailed paired t-test. 
Individual data points are shown. 
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Supplementary Figure 2. Screen candidates gene expression levels. A: Level of 
expression for each candidate gene included in the RNAi screen in MIN6B1 cells. 
Data are expressed as mean ± SEM, n=2, gene expression determined by qRT-PCR 
relative to beta actin (Actb). B: Degree of silencing achieved for each gene tested in 
the RNAi screen in MIN6B1-SNAP-GLP-1R cells. Expression assessed by qRT-PCR 
48 h post-transfection. Data are expressed as mean ± SEM relative to Control RNAi, 
n=2. 
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Supplementary Figure 3. Percentage of SNAP-GLP-1R recycling in Control vs. 
HIP1 RNAi-treated MIN6B1-SNAP-GLP-1R cells. Recycling measured at 30 min 
following a 15 min exendin-4 pulse to induce internalization, in the presence of 
exendin(9-39) to block further endocytosis; data are expressed as mean ± SEM n=3, 
non-significant (n.s.), two-tailed paired t-test. Individual data points are shown. 
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Supplementary Figure 4. Level of expression of GLP-1R in MIN6B1-SNAP-
GLP-1R relative to parental MIN6B1 cells. Expression levels determined by qRT-
PCR for mouse (MIN6B1) vs. human (MIN6B1-SNAP-GLP-1R) GLP-1R mRNA. 
Data are expressed as mean ± SEM relative to MIN6B1 levels; n=12, ***p<0.001, 
two-tailed paired t-test. Individual data points are shown. 
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Supplementary Figure 5. GLP-1-stimulated insulin secretion of Control vs. HIP1 
RNAi-treated MIN6B1 cells. Data are expressed as mean ± SEM of GLP-1 plus 11 
mM glucose (G11) ISI relative to G11 alone; n=5, *p<0.05, two-tailed paired t-test. 
Individual data points are shown. 
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Supplementary Figure 6. Lentiviral HIP1 shRNA additional experiments. A: 
Target sequences for The RNAi Consortium (TRC) lentiviral HIP1 shRNA 
constructs. B, C: Knockdown efficiency relative to Control shRNA after 72 h for the 
5 TRC lentiviral HIP1 shRNA constructs in HEK293T cells (B), and following 
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infection with packaged lentiviral particles from 2 selected HIP1 shRNA sequences in 
human EndoC-βH1 beta cells (C). Data are expressed as mean ± SEM; n=2, *p<0.05 
and **p<0.01 vs. Control shRNA, one-way ANOVA with Dunnett’s test. D: 
Knockdown efficiency determined by qRT-PCR at 72 h from dispersed human islets 
infected with human HIP1 shRNA lentiviruses, relative to Control shRNA infection; 
n=8 for HIP1 shRNA TRCN0000033446 (TRCN446) and n=6 for HIP1 shRNA 
TRCN0000033447 (TRCN447), *p<0.05 and **p<0.01 vs. Control shRNA, one-way 
randomized block ANOVA with Dunnett’s test. Individual data points are shown. E: 
Glucose-stimulated insulin secretion responses from Fig. 4C. Data are expressed as 
mean ± SEM of insulin secreted at G11 as percentage of total insulin; n=4, non-
significant (n.s.) vs. Control shRNA, one-way randomized block ANOVA with 
Dunnett’s test. Individual data points are shown. 
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Supplementary Figure 7. Confocal microscopy of SNAP-GLP-1R and β-arrestin 
constructs under vehicle conditions. SNAP-GLP-1R (labeled with SNAP-Surface-
549, red) and either β-arrestin-1-mYFP (Barr1-mYFP) or β-arrestin-2-GFP (Barr2-
GFP) in Control (top) or HIP1 RNAi-treated (bottom) MIN6B1-SNAP-GLP-1R cells 
without stimulation. Nuclei (DAPI), blue; size bars, 10 µm.   
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Supplementary Figure 8. SNAP-GLP-1R interactions with mutant SNX27-GFP 
vectors. A: Confocal microscopy showing co-localization of SNAP-GLP-1R and 
GFP-tagged SNX27 NPxY (W475A) or ΔPDZ mutants in MIN6B1-SNAP-GLP-1R 
cells following 15 min treatment with 100 nM exendin-4. SNX27-GFP mutants 
(green), SNAP-GLP-1R (labeled with SNAP-Surface-549, red), nuclei (DAPI), blue; 
size bars, 10 µm. B: SNAP-Capture pull-down of SNAP-GLP-1R with mutants from 
(A) in MIN6B1-SNAP-GLP-1R cell lysates after 15 min exposure to 100 nM 
exendin-4 or GLP-1. Pulled-down proteins analyzed by Western blot for GFP, 
original lysates immuno-blotted to assess levels of expression of GFP-tagged SNX27 
mutant constructs. 
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Supplementary Figure 9. Exendin-4-induced cAMP responses in Control vs. 
SNX1 or SNX27 RNAi-treated MIN6B1-SNAP-GLP-1R cells. Cells were exposed 
to 10 min exendin-4 at 100 nM plus 500 µM IBMX. Data are expressed as mean ± 
SEM of exendin-4 plus 500 µM IBMX relative to 500 µM IBMX alone; n=4, *p<0.05 
vs. Control RNAi, one-way randomized block ANOVA with Sidak’s test. Individual 
data points are shown. 
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Supplementary Figure 10. SNAP-GLP-1R localisation in CHO-SNAP-GLP-1R 
cells. Confocal microscopy results showing SNAP-Surface-549-labelled SNAP-GLP-
1R (red) in CHO-SNAP-GLP-1R cells before and after 30 min stimulation with 100 
nM exendin-4. Nuclei (DAPI), blue; size bars, 10 µm. 
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Supplementary Figure 11. Additional experiments in EndoC-βH1 SNX shRNA 
sublines. A: Target sequences for the Control and SNX shRNA constructs used to 
generate the EndoC-βH1 shRNA sublines. B: Knockdown efficiencies relative to 
Control shRNA in EndoC-βH1 SNX1 (left) or SNX27 (right) shRNA sublines. Data 
are expressed as mean ± SEM; n=4, ***p<0.01, two-tailed paired t-test. Individual 
data points are shown. C: GLP-1-induced cAMP following 15 min treatment with 100 
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nM GLP-1 plus 500 µM IBMX in Control vs. SNX1 or SNX27 shRNA EndoC-βH1 
sublines. Data are expressed as mean ± SEM of GLP-1 plus 500 µM IBMX relative to 
500 µM IBMX alone; n=6, *p<0.05, one-way randomized block ANOVA with 
Dunnett’s test. D: GLP-1-stimulated insulin secretion of Control vs. SNX1 or SNX27 
shRNA EndoC-βH1 sublines. Data are expressed as mean ± SEM of GLP-1 plus 15 
mM (G15) glucose ISI relative to G15 alone; n=5, *p<0.05, one-way randomized 
block ANOVA with Dunnett’s test. Individual data points are shown. 
 
Page 58 of 58Diabetes
